Biotie appoints Panu Miettinen CFO
This article was originally published in Scrip
Biotie Therapies, a drug development company focused on neurodegenerative and psychiatric disorders, and inflammatory and fibrotic liver disease, has appointed Panu Miettinen chief financial officer, effective 15 March. Mr Miettinen will be based in Finland reporting to Timo Veromaa, president and CEO. He is replacing Zack McNealy, who has been serving as interim CFO and will resume his prior duties as vice-president of finance and administration at the group's US subsidiary. Mr Miettinen was previously CFO of Elektrobit Corporation.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.